We owe it to ourselves to make sure decisions to regulate access to medical care are based on sound science and a fair and transparent process.

Barack Obama's health policies hamstring community clinics.

If John Kerry's campaign rhetoric matches his governing style, after the election things could get much worse for the scientists and companies that make medical products.

The controversy over aspects of the House health care legislation that have been inappropriately equated with "death panels" has obscured the real problems with these provisions.

We need to design regulatory approaches to ensure that molecular diagnostic tests are reliable while not overburdening those seeking to develop these important new technologies.